{"DataElement":{"publicId":"3351888","version":"1","preferredName":"Prostate Cancer Patient Bone Scan Result Clinical TNM Finding Stage","preferredDefinition":"Text statement to describe the results of a bone scan performed on a patient with prostate cancer.","longName":"3350699v1.0:3351754v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3350699","version":"1","preferredName":"Prostate Carcinoma Patient Bone Scan Result","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A nuclear imaging method used to evaluate pathological bone metabolism._The result of an action.","longName":"3350696v1.0:3350697v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3350696","version":"1","preferredName":"Prostate Carcinoma Patient","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","longName":"C4863:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B655744C-630E-6963-E040-BB89AD433CD0","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3350697","version":"1","preferredName":"Bone Scan Outcome","preferredDefinition":"A nuclear imaging method used to evaluate pathological bone metabolism. :The result of an action.","longName":"C17646:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Scan","conceptCode":"C17646","definition":"A nuclear imaging method used to evaluate pathological bone metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B655744C-631F-6963-E040-BB89AD433CD0","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B655744C-6330-6963-E040-BB89AD433CD0","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Released per approval by B.McClure-Shimel. mc 1/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3351754","version":"1","preferredName":"Bone Scan Prostate Cancer Clinical TNM Finding Stage","preferredDefinition":"A nuclear imaging method used to evaluate pathological bone metabolism._One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_TNM staging performed with access to clinical information only._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3351754v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Abnormal (not related to prostate cancer)","valueDescription":"Abnormal","ValueMeaning":{"publicId":"2562119","version":"1","preferredName":"Abnormal","longName":"2562119","preferredDefinition":"Deviating from the norm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abnormal","conceptCode":"C25401","definition":"Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BFB4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-22","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-22","modifiedBy":"REEVESD","dateModified":"2010-07-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B65DD1CE-FEB1-0EF6-E040-BB89AD435AA2","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Equivocal","valueDescription":"Equivocal","ValueMeaning":{"publicId":"2558729","version":"1","preferredName":"Equivocal","longName":"2558729","preferredDefinition":"Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Equivocal","conceptCode":"C86071","definition":"Open to question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B276-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B65DD1CE-FEBB-0EF6-E040-BB89AD435AA2","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Normal (no evidence of prostate cancer) [cM0]","valueDescription":"Prostate Cancer cM0 TNM Finding v7","ValueMeaning":{"publicId":"3351751","version":"1","preferredName":"Prostate Cancer cM0 TNM Finding v7","longName":"3351751","preferredDefinition":"Prostate cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer cM0 TNM Finding v7","conceptCode":"C89227","definition":"Prostate cancer without evidence of distant metastasis. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65DD1CE-FE3D-0EF6-E040-BB89AD435AA2","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B65DD1CE-FEC5-0EF6-E040-BB89AD435AA2","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Prostate Cancer Metastases Present [cM1b]","valueDescription":"Prostate Cancer cM1b TNM Finding v7","ValueMeaning":{"publicId":"3351749","version":"1","preferredName":"Prostate Cancer cM1b TNM Finding v7","longName":"3351749","preferredDefinition":"Prostate cancer with metastasis to bone(s). (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer cM1b TNM Finding v7","conceptCode":"C89230","definition":"Prostate cancer with metastasis to bone(s). (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65DD1CE-FE17-0EF6-E040-BB89AD435AA2","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B65DD1CE-FECF-0EF6-E040-BB89AD435AA2","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3351753","version":"1","preferredName":"Bone Scan Prostate Carcinoma Clinical TNM Finding Stage","preferredDefinition":"A nuclear imaging method used to evaluate pathological bone metabolism. :Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:TNM staging performed with access to clinical information only.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C17646:C4863:C48881:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Scan","conceptCode":"C17646","definition":"A nuclear imaging method used to evaluate pathological bone metabolism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical TNM Finding","conceptCode":"C48881","definition":"TNM staging performed with access to clinical information only.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65DD1CE-FE8A-0EF6-E040-BB89AD435AA2","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65DD1CE-FE9B-0EF6-E040-BB89AD435AA2","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"COOPERM","dateModified":"2012-01-18","changeDescription":"Released per approval by B.McClure-Shimel. mc 1/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787516","version":"1","longName":"PRAD","context":"NCIP"}]}],"AlternateNames":[{"name":"bone_scan_results","type":"TCGA_XML_Name","context":"NCIP"}],"ReferenceDocuments":[{"name":"Bone Scan Results","type":"Preferred Question Text","description":"Bone Scan Results","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66E5FC3-0868-1D70-E040-BB89AD43721A","latestVersionIndicator":"Yes","beginDate":"2012-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-13","modifiedBy":"TSESU","dateModified":"2018-07-13","changeDescription":"Released by TCGA per approval from B.McClure-Shimel. mc 1/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}